355 related articles for article (PubMed ID: 15299064)
41. CCK-2/gastrin receptor-targeted tumor imaging with (99m)Tc-labeled minigastrin analogs.
Nock BA; Maina T; Béhé M; Nikolopoulou A; Gotthardt M; Schmitt JS; Behr TM; Mäcke HR
J Nucl Med; 2005 Oct; 46(10):1727-36. PubMed ID: 16204724
[TBL] [Abstract][Full Text] [Related]
42. Selective Imaging of VEGFR-1 and VEGFR-2 Using 89Zr-Labeled Single-Chain VEGF Mutants.
Meyer JP; Edwards KJ; Kozlowski P; Backer MV; Backer JM; Lewis JS
J Nucl Med; 2016 Nov; 57(11):1811-1816. PubMed ID: 27390161
[TBL] [Abstract][Full Text] [Related]
43. In vitro evaluation and biodistribution of a 99mTc-labeled anti-VEGF peptide targeting neuropilin-1.
Perret GY; Starzec A; Hauet N; Vergote J; Le Pecheur M; Vassy R; Léger G; Verbeke KA; Bormans G; Nicolas P; Verbruggen AM; Moretti JL
Nucl Med Biol; 2004 Jul; 31(5):575-81. PubMed ID: 15219275
[TBL] [Abstract][Full Text] [Related]
44. Technetium-99m HYNIC-annexin V: a potential radiopharmaceutical for the in-vivo detection of apoptosis.
Ohtsuki K; Akashi K; Aoka Y; Blankenberg FG; Kopiwoda S; Tait JF; Strauss HW
Eur J Nucl Med; 1999 Oct; 26(10):1251-8. PubMed ID: 10541822
[TBL] [Abstract][Full Text] [Related]
45. [99mTc]Demobesin 1, a novel potent bombesin analogue for GRP receptor-targeted tumour imaging.
Nock B; Nikolopoulou A; Chiotellis E; Loudos G; Maintas D; Reubi JC; Maina T
Eur J Nucl Med Mol Imaging; 2003 Feb; 30(2):247-58. PubMed ID: 12552343
[TBL] [Abstract][Full Text] [Related]
46. Myelotoxicity and RBE of 211At-conjugated monoclonal antibodies compared with 99mTc-conjugated monoclonal antibodies and 60Co irradiation in nude mice.
Elgqvist J; Bernhardt P; Hultborn R; Jensen H; Karlsson B; Lindegren S; Warnhammar E; Jacobsson L
J Nucl Med; 2005 Mar; 46(3):464-71. PubMed ID: 15750160
[TBL] [Abstract][Full Text] [Related]
47. Kinetics of 99mTc-labeled interleukin-8 in experimental inflammation and infection.
Rennen HJ; Boerman OC; Oyen WJ; Corstens FH
J Nucl Med; 2003 Sep; 44(9):1502-9. PubMed ID: 12960199
[TBL] [Abstract][Full Text] [Related]
48.
Tesan FC; Nicoud MB; Nuñez M; Medina VA; Chiappetta DA; Salgueiro MJ
Contrast Media Mol Imaging; 2019; 2019():4087895. PubMed ID: 31178670
[TBL] [Abstract][Full Text] [Related]
49. Infection detection in mice using 99mTc-labeled HYNIC and N2S2 chelate conjugated to the antimicrobial peptide UBI 29-41.
Welling MM; Visentin R; Feitsma HI; Lupetti A; Pauwels EK; Nibbering PH
Nucl Med Biol; 2004 May; 31(4):503-9. PubMed ID: 15093821
[TBL] [Abstract][Full Text] [Related]
50. (99m)Tc-labeled SWL specific peptide for targeting EphA2 receptor.
Liu Y; Lan X; Wu T; Lang J; Jin X; Sun X; Wen Q; An R
Nucl Med Biol; 2014 Jul; 41(6):450-6. PubMed ID: 24768147
[TBL] [Abstract][Full Text] [Related]
51. Technetium-99m- Arg-Arg-Leu(g2), a modified peptide probe targeted to neovascularization in molecular tumor imaging.
Lu X; Zhao L; Xue T; Zhang H
J BUON; 2013; 18(4):1074-81. PubMed ID: 24344042
[TBL] [Abstract][Full Text] [Related]
52. Biological evaluation of a technetium-99m-labeled integrated tropane-BAT and its piperidine congener as potential dopamine transporter imaging agents.
Kieffer DM; Vanbilloen HP; Cleynhens BJ; Terwinghe CY; Mortelmans L; Bormans GM; Verbruggen AM
Nucl Med Biol; 2006 Jan; 33(1):125-33. PubMed ID: 16459268
[TBL] [Abstract][Full Text] [Related]
53. Noninvasive visualization of RNA delivery with 99mTc-radiolabeled small-interference RNA in tumor xenografts.
Kang L; Wang RF; Yan P; Liu M; Zhang CL; Yu MM; Cui YG; Xu XJ
J Nucl Med; 2010 Jun; 51(6):978-86. PubMed ID: 20484428
[TBL] [Abstract][Full Text] [Related]
54. (99m)Tc-ixolaris targets glioblastoma-associated tissue factor: in vitro and pre-clinical applications.
Barboza T; Gomes T; Mizurini DM; Monteiro RQ; König S; Francischetti IM; Signoretti PV; Ramos IP; Gutfilen B; Souza SA
Thromb Res; 2015 Aug; 136(2):432-9. PubMed ID: 26070446
[TBL] [Abstract][Full Text] [Related]
55. Chimeric ribonuclease as a source of human adapter protein for targeted drug delivery.
Gaynutdinov TI; Myshkin E; Backer JM; Backer MV
Protein Eng; 2003 Oct; 16(10):771-5. PubMed ID: 14600207
[TBL] [Abstract][Full Text] [Related]
56.
Rezazadeh F; Sadeghzadeh N; Abedi SM; Abediankenari S
Nucl Med Biol; 2018; 62-63():54-62. PubMed ID: 29885559
[TBL] [Abstract][Full Text] [Related]
57. Evaluation of (99m)Tc-HYNIC-TMTP1 as a tumor-homing imaging agent targeting metastasis with SPECT.
Li F; Cheng T; Dong Q; Wei R; Zhang Z; Luo D; Ma X; Wang S; Gao Q; Ma D; Zhu X; Xi L
Nucl Med Biol; 2015 Mar; 42(3):256-62. PubMed ID: 25516099
[TBL] [Abstract][Full Text] [Related]
58. Amplification targeting: a modified pretargeting approach with potential for signal amplification-proof of a concept.
He J; Liu G; Gupta S; Zhang Y; Rusckowski M; Hnatowich DJ
J Nucl Med; 2004 Jun; 45(6):1087-95. PubMed ID: 15181145
[TBL] [Abstract][Full Text] [Related]
59. Radiolabelling of glycosylated MFE-23::CPG2 fusion protein (MFECP1) with 99mTc for quantitation of tumour antibody-enzyme localisation in antibody-directed enzyme pro-drug therapy (ADEPT).
Francis RJ; Mather SJ; Chester K; Sharma SK; Bhatia J; Pedley RB; Waibel R; Green AJ; Begent RH
Eur J Nucl Med Mol Imaging; 2004 Aug; 31(8):1090-6. PubMed ID: 15029458
[TBL] [Abstract][Full Text] [Related]
60. Synthesis, characterization and bioevaluation of technetium-99m labeled N-(2-Hydroxybenzyl)-2-amino-2-deoxy-D-glucose as a tumor imaging agent.
Nadeem Q; Khan I; Javed M; Mahmood Z; Dar UK; Ali M; Hyder SW; Murad S
Pak J Pharm Sci; 2013 Mar; 26(2):353-7. PubMed ID: 23455207
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
